ReP USP - Resultado da busca

Artigo de periodico
Sex differences in GABAA receptor subunit transcript expression are mediated by genotype in subjects with alcohol-related cirrhosis of the liver (2022)
Ashton, Madeline K.; Rueda, André Veloso Lima ; Ho, Ada M. C. ; Aizin, Noradibah Arina Binte M. Noor; Sharma, Hansa ; Dodd, Peter R. ; Stadlin, Alfreda ; Camarini, Rosana
Source: Genes, Brain and Behavior. Unidade: ICB
Subjects: FARMACOLOGIA, CIRROSE HEPÁTICA, ABUSO DE ÁLCOOL, GABA, GENÓTIPOS, INTERAÇÃO GENÓTIPO-AMBIENTE, FENÓTIPOS, REAÇÃO EM CADEIA POR POLIMERASE, SEXO, POLIMORFISMO, ALCOOLISMO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ASHTON, Madeline K. et al. Sex differences in GABAA receptor subunit transcript expression are mediated by genotype in subjects with alcohol-related cirrhosis of the liver. Genes, Brain and Behavior, p. 1-14, 2022Tradução . . Disponível em: https://doi.org/10.1111/gbb.12785. Acesso em: 08 nov. 2024.
APA
Ashton, M. K., Rueda, A. V. L., Ho, A. M. C., Aizin, N. A. B. M. N., Sharma, H., Dodd, P. R., et al. (2022). Sex differences in GABAA receptor subunit transcript expression are mediated by genotype in subjects with alcohol-related cirrhosis of the liver. Genes, Brain and Behavior, 1-14. doi:10.1111/gbb.12785
NLM
Ashton MK, Rueda AVL, Ho AMC, Aizin NABMN, Sharma H, Dodd PR, Stadlin A, Camarini R. Sex differences in GABAA receptor subunit transcript expression are mediated by genotype in subjects with alcohol-related cirrhosis of the liver [Internet]. Genes, Brain and Behavior. 2022 ; 1-14.[citado 2024 nov. 08 ] Available from: https://doi.org/10.1111/gbb.12785
Vancouver
Ashton MK, Rueda AVL, Ho AMC, Aizin NABMN, Sharma H, Dodd PR, Stadlin A, Camarini R. Sex differences in GABAA receptor subunit transcript expression are mediated by genotype in subjects with alcohol-related cirrhosis of the liver [Internet]. Genes, Brain and Behavior. 2022 ; 1-14.[citado 2024 nov. 08 ] Available from: https://doi.org/10.1111/gbb.12785
Artigo de periodico
Cholinergic neuroplasticity in asthma driven by TrkB signaling (2020)
Dragunas, Guilherme ; Woest, Manon E.; Nijboer, Susan; Bos, Sophie T.; Asselt, Janet van; Groot, Anne P. de; Vohlídalová, Eva ; Vermeulen, Corneel J. ; Ditz, Benedikt ; Vonk, Judith M. ; Koppelman, Gerard H. ; Berge, Maarten van den ; Hacken, Nick H. T. ten ; Timens, Wim ; Munhoz, Carolina Demarchi ; Prakash, Y. S. ; Gosens, Reinoud; Kistemaker, Loes E. M.
Source: FASEB Journal. Unidade: ICB
Subjects: FARMACOLOGIA, PLASTICIDADE NEURONAL, ASMA, CAMUNDONGOS, EXPRESSÃO GÊNICA, COLINÉRGICOS, NEURÔNIOS, POLIMORFISMO, ALÉRGENOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DRAGUNAS, Guilherme et al. Cholinergic neuroplasticity in asthma driven by TrkB signaling. FASEB Journal, v. 34, n. 6, p. 7703-7717, 2020Tradução . . Disponível em: https://doi.org/10.1096/fj.202000170R. Acesso em: 08 nov. 2024.
APA
Dragunas, G., Woest, M. E., Nijboer, S., Bos, S. T., Asselt, J. van, Groot, A. P. de, et al. (2020). Cholinergic neuroplasticity in asthma driven by TrkB signaling. FASEB Journal, 34( 6), 7703-7717. doi:10.1096/fj.202000170R
NLM
Dragunas G, Woest ME, Nijboer S, Bos ST, Asselt J van, Groot AP de, Vohlídalová E, Vermeulen CJ, Ditz B, Vonk JM, Koppelman GH, Berge M van den, Hacken NHT ten, Timens W, Munhoz CD, Prakash YS, Gosens R, Kistemaker LEM. Cholinergic neuroplasticity in asthma driven by TrkB signaling [Internet]. FASEB Journal. 2020 ; 34( 6): 7703-7717.[citado 2024 nov. 08 ] Available from: https://doi.org/10.1096/fj.202000170R
Vancouver
Dragunas G, Woest ME, Nijboer S, Bos ST, Asselt J van, Groot AP de, Vohlídalová E, Vermeulen CJ, Ditz B, Vonk JM, Koppelman GH, Berge M van den, Hacken NHT ten, Timens W, Munhoz CD, Prakash YS, Gosens R, Kistemaker LEM. Cholinergic neuroplasticity in asthma driven by TrkB signaling [Internet]. FASEB Journal. 2020 ; 34( 6): 7703-7717.[citado 2024 nov. 08 ] Available from: https://doi.org/10.1096/fj.202000170R
Artigo de periodico
An update on efflux and uptake transporters as determinants of statin response (2018)
Rocha, Karina Cunha e ; Pereira, Beatriz Maria Veloso ; Rodrigues, Alice Cristina
Source: Expert Opinion on Drug Metabolism & Toxicology. Unidade: ICB
Subjects: FARMACOLOGIA, POLIMORFISMO, ESTATINAS, INIBIDORES DE ENZIMAS, DOENÇAS CARDIOVASCULARES, TRANSPORTE BIOLÓGICO, VARIAÇÃO GENÉTICA, DISLIPIDEMIAS, INTERAÇÃO DE DROGAS, TRANSPORTE ATRAVÉS DA MEMBRANA, MICRORNAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ROCHA, Karina Cunha e e PEREIRA, Beatriz Maria Veloso e RODRIGUES, Alice Cristina. An update on efflux and uptake transporters as determinants of statin response. Expert Opinion on Drug Metabolism & Toxicology, v. 14, n. 6, p. 613–624, 2018Tradução . . Disponível em: https://doi.org/10.1080/17425255.2018.1482276. Acesso em: 08 nov. 2024.
APA
Rocha, K. C. e, Pereira, B. M. V., & Rodrigues, A. C. (2018). An update on efflux and uptake transporters as determinants of statin response. Expert Opinion on Drug Metabolism & Toxicology, 14( 6), 613–624. doi:10.1080/17425255.2018.1482276
NLM
Rocha KC e, Pereira BMV, Rodrigues AC. An update on efflux and uptake transporters as determinants of statin response [Internet]. Expert Opinion on Drug Metabolism & Toxicology. 2018 ; 14( 6): 613–624.[citado 2024 nov. 08 ] Available from: https://doi.org/10.1080/17425255.2018.1482276
Vancouver
Rocha KC e, Pereira BMV, Rodrigues AC. An update on efflux and uptake transporters as determinants of statin response [Internet]. Expert Opinion on Drug Metabolism & Toxicology. 2018 ; 14( 6): 613–624.[citado 2024 nov. 08 ] Available from: https://doi.org/10.1080/17425255.2018.1482276
Artigo de periodico
Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients (2016)
Genvigir, F. D. V.; Salgado, P. C.; Felipe, C. R.; Luo, E. Y. F.; Alves, C.; Cerda, A.; Silva Junior, H. T.; Pestana, J. O. M.; Oliveira, N.; Rodrigues, Alice Cristina ; Doi, S. Q.; Hirata, Mario Hiroyuki ; Hirata, Rosario Dominguez Crespo
Source: Pharmacogenetics and Genomics. Unidades: ICB, FCF
Subjects: POLIMORFISMO, FÁRMACOS IMUNOSSUPRESSORES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GENVIGIR, F. D. V. et al. Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients. Pharmacogenetics and Genomics, v. 26, n. 10, p. 462-472, 2016Tradução . . Disponível em: https://doi.org/10.1097/FPC.0000000000000237. Acesso em: 08 nov. 2024.
APA
Genvigir, F. D. V., Salgado, P. C., Felipe, C. R., Luo, E. Y. F., Alves, C., Cerda, A., et al. (2016). Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients. Pharmacogenetics and Genomics, 26( 10), 462-472. doi:10.1097/FPC.0000000000000237
NLM
Genvigir FDV, Salgado PC, Felipe CR, Luo EYF, Alves C, Cerda A, Silva Junior HT, Pestana JOM, Oliveira N, Rodrigues AC, Doi SQ, Hirata MH, Hirata RDC. Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients [Internet]. Pharmacogenetics and Genomics. 2016 ; 26( 10): 462-472.[citado 2024 nov. 08 ] Available from: https://doi.org/10.1097/FPC.0000000000000237
Vancouver
Genvigir FDV, Salgado PC, Felipe CR, Luo EYF, Alves C, Cerda A, Silva Junior HT, Pestana JOM, Oliveira N, Rodrigues AC, Doi SQ, Hirata MH, Hirata RDC. Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients [Internet]. Pharmacogenetics and Genomics. 2016 ; 26( 10): 462-472.[citado 2024 nov. 08 ] Available from: https://doi.org/10.1097/FPC.0000000000000237
Artigo de periodico
ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib (2014)
Vivona, Douglas; Lima, Luciene Terezin; Rodrigues, Alice Cristina ; Bueno, Carolina Tosin; Alcantara, Greyce Kelly Steinhorst; Barros, Luiza Saldanha Ribeiro; Hungria, Vania Tietsche de Moraes; Chiattone, Carlos Sérgio; Chauffaille, Maria de Lourdes Lopes Ferrari; Guerra-Shinohara, Elvira Maria
Source: Oncology Letters. Unidades: ICB, FCF
Subjects: LEUCEMIA MIELOIDE, POLIMORFISMO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VIVONA, Douglas et al. ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib. Oncology Letters, v. 7, n. 4, p. 1313-1319, 2014Tradução . . Disponível em: https://doi.org/10.3892/ol.2014.1857. Acesso em: 08 nov. 2024.
APA
Vivona, D., Lima, L. T., Rodrigues, A. C., Bueno, C. T., Alcantara, G. K. S., Barros, L. S. R., et al. (2014). ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib. Oncology Letters, 7( 4), 1313-1319. doi:10.3892/ol.2014.1857
NLM
Vivona D, Lima LT, Rodrigues AC, Bueno CT, Alcantara GKS, Barros LSR, Hungria VT de M, Chiattone CS, Chauffaille M de LLF, Guerra-Shinohara EM. ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib [Internet]. Oncology Letters. 2014 ; 7( 4): 1313-1319.[citado 2024 nov. 08 ] Available from: https://doi.org/10.3892/ol.2014.1857
Vancouver
Vivona D, Lima LT, Rodrigues AC, Bueno CT, Alcantara GKS, Barros LSR, Hungria VT de M, Chiattone CS, Chauffaille M de LLF, Guerra-Shinohara EM. ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib [Internet]. Oncology Letters. 2014 ; 7( 4): 1313-1319.[citado 2024 nov. 08 ] Available from: https://doi.org/10.3892/ol.2014.1857
Artigo de periodico
Influence of SLCO1B1 and SLCO2B1 polymorphisms on tacrolimus pharmacokinetics and clinical response (2014)
Alves, Camila; Felipe, Claudia Rosso; Nishikawa, Alvaro Mitsunori; Salgado, Patricia de Cássia; Fajardo, Cristina Moreno ; Silva Junior, Helio Tedesco; Pestana, Jose Osmar Medina; Zetchaku, Denize; Spinelli, Glaucio; Oliveira, Nagilla; Hirata, Mario Hiroyuki ; Hirata, Rosario Dominguez Crespo ; Rodrigues, Alice Cristina
Source: Journal Pharmacogenomics Pharmacoproteomics. Unidades: FCF, ICB
Subjects: POLIMORFISMO, FARMACOCINÉTICA, TRANSPLANTE DE RIM
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ALVES, Camila et al. Influence of SLCO1B1 and SLCO2B1 polymorphisms on tacrolimus pharmacokinetics and clinical response. Journal Pharmacogenomics Pharmacoproteomics, v. 5, n. 3, p. 1-16 art. 1000134, 2014Tradução . . Disponível em: https://doi.org/10.4172/2153-0645.1000134. Acesso em: 08 nov. 2024.
APA
Alves, C., Felipe, C. R., Nishikawa, A. M., Salgado, P. de C., Fajardo, C. M., Silva Junior, H. T., et al. (2014). Influence of SLCO1B1 and SLCO2B1 polymorphisms on tacrolimus pharmacokinetics and clinical response. Journal Pharmacogenomics Pharmacoproteomics, 5( 3), 1-16 art. 1000134. doi:10.4172/2153-0645.1000134
NLM
Alves C, Felipe CR, Nishikawa AM, Salgado P de C, Fajardo CM, Silva Junior HT, Pestana JOM, Zetchaku D, Spinelli G, Oliveira N, Hirata MH, Hirata RDC, Rodrigues AC. Influence of SLCO1B1 and SLCO2B1 polymorphisms on tacrolimus pharmacokinetics and clinical response [Internet]. Journal Pharmacogenomics Pharmacoproteomics. 2014 ; 5( 3): 1-16 art. 1000134.[citado 2024 nov. 08 ] Available from: https://doi.org/10.4172/2153-0645.1000134
Vancouver
Alves C, Felipe CR, Nishikawa AM, Salgado P de C, Fajardo CM, Silva Junior HT, Pestana JOM, Zetchaku D, Spinelli G, Oliveira N, Hirata MH, Hirata RDC, Rodrigues AC. Influence of SLCO1B1 and SLCO2B1 polymorphisms on tacrolimus pharmacokinetics and clinical response [Internet]. Journal Pharmacogenomics Pharmacoproteomics. 2014 ; 5( 3): 1-16 art. 1000134.[citado 2024 nov. 08 ] Available from: https://doi.org/10.4172/2153-0645.1000134
Artigo de periodico
Inﬂuence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects (2014)
Anderson, Jacqueline M.; Cerda, Alvaro ; Hirata, Mario Hiroyuki ; Rodrigues, Alice Cristina ; Dórea, Egidio Lima; Bernik, Marcia Martins Silveira; Bertolami, Marcelo Chiara ; Faludi, André Arpad; Hirata, Rosario Dominguez Crespo
Source: Journal of Clinical Lipidology. Unidades: FCF, ICB, HU
Subjects: POLIMORFISMO, COLESTEROL, FARMACOLOGIA, LIPÍDEOS, NUCLEOTÍDEOS, FARMACOGENÉTICA, LIPOPROTEÍNAS LDL, REAÇÃO EM CADEIA POR POLIMERASE, PLASMA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ANDERSON, Jacqueline M. et al. Inﬂuence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects. Journal of Clinical Lipidology, v. 8, n. 3, p. 256-264, 2014Tradução . . Disponível em: https://doi.org/10.1016/j.jacl.2014.02.008. Acesso em: 08 nov. 2024.
APA
Anderson, J. M., Cerda, A., Hirata, M. H., Rodrigues, A. C., Dórea, E. L., Bernik, M. M. S., et al. (2014). Inﬂuence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects. Journal of Clinical Lipidology, 8( 3), 256-264. doi:10.1016/j.jacl.2014.02.008
NLM
Anderson JM, Cerda A, Hirata MH, Rodrigues AC, Dórea EL, Bernik MMS, Bertolami MC, Faludi AA, Hirata RDC. Inﬂuence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects [Internet]. Journal of Clinical Lipidology. 2014 ; 8( 3): 256-264.[citado 2024 nov. 08 ] Available from: https://doi.org/10.1016/j.jacl.2014.02.008
Vancouver
Anderson JM, Cerda A, Hirata MH, Rodrigues AC, Dórea EL, Bernik MMS, Bertolami MC, Faludi AA, Hirata RDC. Inﬂuence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects [Internet]. Journal of Clinical Lipidology. 2014 ; 8( 3): 256-264.[citado 2024 nov. 08 ] Available from: https://doi.org/10.1016/j.jacl.2014.02.008
Trabalho de evento-resumo periodico
ABCB1 haplotype is associated with alterations in functional activity of P-GP and affects major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib (2013)
Vivona, Douglas; Lima, L; Rodrigues, Alice Cristina ; Bueno, Carolina Tosin; Chauffaille, Maria de Lourdes Lopes Ferrari; Chiattone, Carlos Sérgio; Hungria, Vania Tietsche de Moraes; Guerra-Shinohara, Elvira Maria
Source: Haematologica. Conference titles: Congress of the European Hematology Association. Unidades: ICB, FCF
Subjects: LEUCEMIA MIELOIDE, POLIMORFISMO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VIVONA, Douglas et al. ABCB1 haplotype is associated with alterations in functional activity of P-GP and affects major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib. Haematologica. Pavia: Instituto de Ciências Biomédicas, Universidade de São Paulo. . Acesso em: 08 nov. 2024. , 2013
APA
Vivona, D., Lima, L., Rodrigues, A. C., Bueno, C. T., Chauffaille, M. de L. L. F., Chiattone, C. S., et al. (2013). ABCB1 haplotype is associated with alterations in functional activity of P-GP and affects major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib. Haematologica. Pavia: Instituto de Ciências Biomédicas, Universidade de São Paulo.
NLM
Vivona D, Lima L, Rodrigues AC, Bueno CT, Chauffaille M de LLF, Chiattone CS, Hungria VT de M, Guerra-Shinohara EM. ABCB1 haplotype is associated with alterations in functional activity of P-GP and affects major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib. Haematologica. 2013 ; 98 404 res. P978.[citado 2024 nov. 08 ]
Vancouver
Vivona D, Lima L, Rodrigues AC, Bueno CT, Chauffaille M de LLF, Chiattone CS, Hungria VT de M, Guerra-Shinohara EM. ABCB1 haplotype is associated with alterations in functional activity of P-GP and affects major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib. Haematologica. 2013 ; 98 404 res. P978.[citado 2024 nov. 08 ]
Trabalho de evento-resumo
ABCB1 haplotypes are associated with lower P-Gp activity and major molecular response but do not affect imatinib plasma levels in chronic myeloid leukemia patients (2013)
Vivona, Douglas; Lima, Luciene Terezina de; Rodrigues, Alice Cristina ; Bueno, Carolina Tosin; Galtani, Cristiane M; Chiattone, Carlos Sérgio; Hungria, Vania Tietsche de Moraes; Chauffaille, Maria de Lourdes Lopes Ferrari; Guerra-Shinohara, Elvira Maria
Source: Abstracts. Conference titles: American Society of Hematology Annual Meeting and Exposition. Unidades: ICB, FCF
Subjects: LEUCEMIA MIELOIDE, POLIMORFISMO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VIVONA, Douglas et al. ABCB1 haplotypes are associated with lower P-Gp activity and major molecular response but do not affect imatinib plasma levels in chronic myeloid leukemia patients. 2013, Anais.. Oxford: american Society of Hematology, 2013. . Acesso em: 08 nov. 2024.
APA
Vivona, D., Lima, L. T. de, Rodrigues, A. C., Bueno, C. T., Galtani, C. M., Chiattone, C. S., et al. (2013). ABCB1 haplotypes are associated with lower P-Gp activity and major molecular response but do not affect imatinib plasma levels in chronic myeloid leukemia patients. In Abstracts. Oxford: american Society of Hematology.
NLM
Vivona D, Lima LT de, Rodrigues AC, Bueno CT, Galtani CM, Chiattone CS, Hungria VT de M, Chauffaille M de LLF, Guerra-Shinohara EM. ABCB1 haplotypes are associated with lower P-Gp activity and major molecular response but do not affect imatinib plasma levels in chronic myeloid leukemia patients. Abstracts. 2013 ;[citado 2024 nov. 08 ]
Vancouver
Vivona D, Lima LT de, Rodrigues AC, Bueno CT, Galtani CM, Chiattone CS, Hungria VT de M, Chauffaille M de LLF, Guerra-Shinohara EM. ABCB1 haplotypes are associated with lower P-Gp activity and major molecular response but do not affect imatinib plasma levels in chronic myeloid leukemia patients. Abstracts. 2013 ;[citado 2024 nov. 08 ]

USP Schools

ReP

Filtros

Authors

USP affiliated authors

Date published

Subjects

Source title

Funding Agencies

Indexado em

Non normalized affiliation

Countries of institutions of collaboration